Obesity is a chronic complex disease characterized by excessive adiposity that increases risk for multiple noncommunicable diseases including type 2 diabetes, cardiovascular disease, and some cancers.
A Cochrane meta-analysis of 22 studies with nearly 2,000 participants found intermittent fasting is not particularly effective for weight loss in obese or overweight adults and does not differ significantly from standard dietary advice. Experts note it remains an alternative at least as effective as classic calorie restriction, but more long-term trials are needed.
AbbVie will present new lung cancer data at WCLC 2026, including Phase 1b results for ABBV-1480 showing high response rates in NSCLC and safety updates for ABBV-706 in SCLC. The company also reported progress in dermatology, obesity, and Crohn's disease programs.
A study in Life Metabolism shows that a single post-meal blood biomarker, 1-hour postprandial SPARC, predicts who benefits most from a Mediterranean diet. Lower baseline SPARC-1H levels were linked to greater improvements in insulin resistance and glucose control in a six-month trial.
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
A Cochrane review found intermittent fasting did not beat standard diet advice for weight loss. A separate trial found it matched calorie restriction but felt less restrictive. Experts advise a case-by-case approach given limited evidence.
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
Blockbuster drugs worth hundreds of billions face generic competition as patents expire through 2032. Indian drugmakers could capture $3-5 billion of the opportunity, while GSK and Bristol Myers Squibb prepare for revenue losses.
Insilico Medicine named ISM9528 as its 31st AI-driven preclinical pain candidate, published a target discovery study for a rare sinonasal cancer, and advanced partnerships with MSK and Takeda. The company is also presenting oncology programs at AACR 2026.
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07780058 |
Longitudinal Study of the Psychological Impact of Bariatric Surgery |
RECRUITING | |
| NCT07775404 |
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE3 |
| NCT07770893 |
Acupoint Catgut Embedding With Laser Acupuncture for Weight Loss in Adults With Obesity |
NOT_YET_RECRUITING | NA |
| NCT07770841 |
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight |
RECRUITING | PHASE3 |
| NCT07770633 |
Negative Pressure Wound Therapy Devices in Total Knee Arthroplasty |
NOT_YET_RECRUITING | NA |
| NCT07770152 |
Semaglutide in Youth With Autism Spectrum Disorder |
NOT_YET_RECRUITING | PHASE4 |
| NCT07768813 |
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07767175 |
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07765758 |
Prospective Evaluation of Stapled Intact-Duodenum Bipartition With Sleeve Gastrectomy (SIBS) |
NOT_YET_RECRUITING | NA |
| NCT07765511 |
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE1 |
